Zacks.com on MSN13h
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...
Kauppalehti14h
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Dr. Frank Mathias, Chief Executive Officer of OXB, said, “We are delighted that Boehringer Ingelheim is using OXB’s proprietary lentiviral vector manufacturing technology, to produce lentiviral vector ...
Zealand Pharma Announces Financial Results for the Full Year 2024
Company announcement - No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeli ...